(1R,10S,11R)-6-acetyl-10,16-dihydroxy-21-(2-phenylethyl)-4,21-diazapentacyclo[9.7.3.01,10.03,8.013,18]henicosa-3(8),6,13(18),14,16-pentaen-5-one

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 吗啡烷
• 英文名称: (1R,10S,11R)-6-acetyl-10,16-dihydroxy-21-(2-phenylethyl)-4,21-diazapentacyclo[9.7.3.01,10.03,8.013,18]henicosa-3(8),6,13(18),14,16-pentaen-5-one
• 化学式: C₂₉H₃₀N₂O₄
• 分子量: 470.6
• InChiKey: AZKHGYXMOPBAQC-CRXYYGHGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  35
• 可旋转键数：
  4
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  89.9
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• Pyridonemorphinan Analogs and Biological Activity on Opioid Receptors
  申请人：Purdue Pharma L.P.

  公开号：US20140187549A1

  公开（公告）日：2014-07-03

  The application is directed to compounds of Formula I-A and pharmaceutically acceptable salts and solvates thereof, wherein , R 1a , R 3a , R 4 , Y and Z a are defined as set forth in the specification. The invention is also directed to use of compounds of Formula I-A to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates. Certain compounds of the present invention are especially useful for treating pain.
• PYRIDONEMORPHINAN ANALOGS AND BIOLOGICAL ACTIVITY ON OPIOID RECEPTORS
  申请人：Purdue Pharma L.P.

  公开号：US20150203494A1

  公开（公告）日：2015-07-23

  The application is directed to compounds of Formula I-A and pharmaceutically acceptable salts and solvates thereof, wherein , R 1a -R 3a , R 4 , Y and Z a are defined as set forth in the specification. The invention is also directed to use of compounds of Formula I-A to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates. Certain compounds of the present invention are especially useful for treating pain.
• US8980906B2
  申请人：——

  公开号：US8980906B2

  公开（公告）日：2015-03-17
• US9403824B2
  申请人：——

  公开号：US9403824B2

  公开（公告）日：2016-08-02